ELISTAIR
8.6.2020 19:33:06 CEST | Business Wire | Press release
Elistair has announced the release of the Safe-T 2, their most advanced and powerful tethering system for use with commercially available drones. Key Features include IP54 rating, up to 125m / 400 feet micro-tether, 2 200 watts max continuous power, fiber optics option, and industry leading weight/power ratio from its patented Dynamic Voltage Optimization (DVO). The Safe-T 2 provides users with unmatched power efficiency and enables safe persistent flight time for UAVs .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005629/en/
SAFE-T 2 Video: https://youtu.be/9hBA41eDXHM
Since the launch of its first tethering station in 2015, Elistair has quickly become the industry leader in tethered drone systems with over 600 stations deployed to help security forces monitor events, secure sites, protect assets. The Safe-T 2 which has been built on the success of the Safe-T product line, deployed in over 60 countries by governmental organisations, industrial groups, and security forces will take tethering operations to a new level.
“To design the Safe-T 2, we worked in close collaboration with users who challenged us with their critical feedback. We rethought the entire solution to build the perfect tethering system for security operations.” Said Timothée PENET, Elistair Co-founder and CTO. “With up to 2,2 kW max continuous power and 2,8 kW peak power, it allows for higher flights with heavier payloads, thus enabling security forces to cover larger areas with a single system.”
Smart and Secured
The secure Dual-Comms option (Fiber optic and BPL), offers a redundant tethered data link or the possibility to select the best suited technology for the aircraft or payload. A patented Brake system allows the user to adapt the maximal tether length, depending on the safety zone needed, for instance in urban or crowded environments. Like its predecessor, the Safe-T 2 integrates Elistair’s live flight management system with T-monitor application offering optimal flight control for safer operations.
Ready for integration
Engineered to meet the most demanding missions with its rugged weather-resistant design, and compact modular metallic structure, the Safe-T 2 offers mounting plates and optional software development kit (SDK) for seamless integration into vehicles and fixed structures whilst also being agile enough for a single operator to deploy. Its interchangeable micro-tethers and smart adaptive winch control laws allow the operator to reconfigure the station and use the best tether weight/power range for each drone.
More information: www.elistair.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005629/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom